---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-24-000065"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:25:50.450231+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics appoints Mark S. Davis to Board, expanding to nine members

## Summary
- Mark S. Davis appointed as Class I Director effective December 10, 2024, expanding Board from eight to nine.
- Davis will serve on Audit and Finance Committee; deemed independent and an audit committee financial expert.
- Received restricted stock unit award of $350,000 vesting one year from grant date.
- Davis spent nearly 40 years at Deloitte & Touche LLP, last as National Managing Partner of Deloitte Private.
- Also serves on boards of Yext, Inc., NYU-Winthrop Hospital, and Adelphi University.

## SEC filing metadata
- accession: 0000899923-24-000065
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992324000065/0000899923-24-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992324000065/mygn-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-24-000065
- JSON: https://secwatch.observer/filing/0000899923-24-000065.json
- Plain text: https://secwatch.observer/filing/0000899923-24-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.